“Sales Force Effectiveness” and “Marketing Effectiveness” solutions company marketRx received $10.25 million in Series C equity financing from Andwel Partners and WestBridge Capital Partners. Other marquee investors include three Emeritus Chairmen of leading global pharmaceutical companies.

The investors include Robert P. Luciano (Chairman Emeritus of Schering-Plough), Charles Sanders (Former Chairman and CEO of Glaxo, Inc.), Rick S. Braddock (Chairman, Priceline.com), William Shreyer (Chairman Emeritus, Merrill Lynch and Co., Inc.) and Dennis Turner (Ex-CEO and Chairman, PMSI, Inc.)

The funds will be used to sustain the company's impressive growth plan. “Our team started out to change the sales and marketing paradigm in the industry and providing solutions that are in tune with the needs of the industry over the next several years. We are happy to see that pharmaceutical industry executives have embraced our solutions and the value they provide to both strategic and tactical teams within their organizations,” says Jassi Chadha, CEO and President of marketRx.

“The next generation of marketing and sales effectiveness solutions from marketRx embrace the power of advanced analytics and technology to provide much needed solutions to improve the sales and marketing effectiveness in the industry at strategic and tactical levels,” said Rick Braddock, Chairman, priceline.com.

“With strong success with customers, an impressive array of comprehensive solutions and sound leadership, marketRx is poised to be a leading, successful global player in the pharmaceutical sales and marketing effectiveness arena,” said Sumir Chadha, Senior Managing Director of WestBridge Capital Partners.